United States
Choose your country or region:
France
Germany
Italy
Japan
United Kingdom
About
Leadership
Board of Directors
Company History
Corporate Impact and Community Relations
Health Equity
Our Collaborations
Contact Us
Newsroom
News & Stories
Press Releases
Multimedia
Our Tests
Cologuard®
OncoExTra®
Oncoguard® Liver
Oncotype DX®
Oncotype DX Breast DCIS Score®
Oncotype DX Breast Recurrence Score®
Oncotype DX Colon Recurrence Score®
Riskguard™
Provider
Patient
Pipeline & Data
Breast Radiation Score
Next Generation Cologuard
Colorectal Cancer Blood
LBgard® Blood Tubes
Molecular Residual Disease
Cancerguard™
Our Expertise
Cancerguard™ Science
Multi-Cancer Early Detection Thought Leadership
Clinical Studies
Research
Publications & Abstracts
Exact Academy
Investor Relations
Press Releases
Events & Presentations
Environmental, Social, and Governance (ESG)
Stock Information
Financial Information
Email Alerts
Contact Us
Join Our Team
×
DIGITAL NEWSROOM
Posts in:
Exact Sciences News
May 24, 2024
Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®
May 22, 2024
Exact Sciences Earns 2024 Great Place To Work
®
Certification
™
May 21, 2024
Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy
May 07, 2024
Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening with Multiple Data Presentations at DDW
®
2024
April 05, 2024
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-cancer
March 01, 2024
EXACT SCIENCES LAUNCHES RISKGUARD™ HEREDITARY CANCER TEST IN THE UNITED STATES
January 07, 2024
Exact Sciences Announces Preliminary Fourth Quarter 2023 Results
November 30, 2023
Exact Sciences Presents Multiple Studies at San Antonio Breast Cancer Symposium Supporting Optimization and individualization of therapy for breast cancer patients
November 20, 2023
Exact Sciences Presents New Long-Term Patient Outcomes In Multi-Cancer Early Detection And Breast Cancer Recurrence Testing at ASCO
®
2023
June 20, 2023
Next Generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent specificity, Raising the Bar in Non-invasive Screening
June 01, 2023
EXACT SCIENCES EARNS 2023 GREAT PLACE TO WORK
®
CERTIFICATION
™
May 09, 2023
Exact Sciences Extends Leadership in Colorectal Cancer Screening with New Data Presented at Digestive Disease Week
®
Annual Meeting
1
2
3
4
5
6
7
8
9